Gilead Sciences names new CMO

US antivirals major Gilead Sciences (Nasdaq: GILD) announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief medical officer (CMO) and will become a member of Gilead’s senior leadership team. Dr Berger succeeds Dr Merdad Parsey.

Dr Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the company’s leading virology, oncology and inflammation portfolio and will oversee the company’s global development and medical affairs organizations.

“Dietmar’s exceptional leadership in global drug development, his track record in delivering transformational therapies, and the breadth and depth of his experience make him an ideal choice as Gilead’s chief medical officer,” said Daniel O’Day, chairman and chief executive of Gilead, adding: “We are delighted to welcome Dietmar to Gilead at a time when we are poised to extend our leadership in virology and deliver on our significant potential in oncology and inflammation. We look forward to having Dietmar take up his role at the beginning of 2025 as we work to strengthen our impact for patients and communities worldwide.”